Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced multiple subscriptions for structured deposits with CITIC Bank, CZB, and CMB, amounting to significant investments in wealth management products. These transactions, totaling RMB850 million, are considered discloseable under the Hong Kong Stock Exchange Listing Rules due to their substantial financial ratios. This strategic financial positioning indicates the company’s active management of its capital and investment portfolio, potentially impacting its liquidity and market position.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates in the biopharmaceutical industry and is incorporated in the People’s Republic of China. The company engages in the development and production of biopharmaceutical products, focusing on innovative treatments and therapies to address various health conditions.
YTD Price Performance: 2.69%
Average Trading Volume: 307,278
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$37.37B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.
